Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 308

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 308
---
 diagnostic screening. Kira S. Sheinerman and Samuil Umansky. Expert 
 Review of Molecular Diagnostics, 3:329 (2015)                                                                     |

| 8. | Analysis of organ-enriched microRNAs in plasma as an approach                                                
 to development of Universal Screening Test: feasibility study. Kira S. Sheinerman, Vladimir G. Tsivinsky and 
 Samuil R. Umansky. Journal of Translational Medicine, 11:304 (2013)                                          |

| 9. | Plasma microRNA biomarkers for detection of mild cognitive                                                        
 impairment: biomarker validation study. Kira S. Sheinerman, Vladimir G. Tsivinsky, Laila Abdullah, Fiona Crawford 
 and Samuil R. Umansky. Aging, 5: 925-938 (2013)                                                                   |

| 10. | Circulating cell-free microRNA as biomarkers for screening,                                                                         
 diagnosis, and monitoring of neurodegenerative diseases and other neurologic pathologies. Kira S. Sheinerman and Samuil R. Umansky. 
 Frontiers in Cellular Neuroscience, 7: 00150 (2013)                                                                                 |

| 11. | Early detection of neurodegenerative diseases: Circulating                                                
 brain-enriched microRNA. Kira S. Sheinerman and Samuil R. Umansky (Editorial). Cell Cycle, 12: 1-2 (2013) |

| 12. | Plasma microRNA biomarkers for detection of mild cognitive                                                                       
 impairment. Kira S. Sheinerman, Vladimir G. Tsivinsky, Fiona Crawford, Michael J. Mullan, Laila Abdullah, and Samuil R. Umansky. 
 Aging, 4: 590-607 (2012)                                                                                                         |

DiamiR’s data was also
presented at numerous scientific and industry conferences, most recently:

Child Neurology Society, October 2023,
Vancouver, Canada,

Rett Syndrome Foundation Research
Trust Conference, September 2023, Boston MA,

Alzheimer’s Association
International Conference 2023, Amsterdam, Netherlands,

15Clinical Trials
on Alzheimer’s Disease (CTAD), San Francisco, CA,

Alzheimer’s Association
International Conference 2022, San Diego, CA.

<div align='center'>176</div>

Grants and Awards

Since its inception, DiamiR
has raised over $9.7 million grant funding